Several cardiovascular disorders, including atherosclerosis, are associated with endothelial dysfunction and enhanced expression of endothelin-1 (ET-1). The role of ET-1 in the development of endothelial dysfunction in vivo remains unclear. The objective of the present study was to investigate the effect of elevated circulating levels of ET-1 on endothelium-dependent vasodilatation (EDV), and to test the hypothesis that ET A receptor antagonism improves EDV in patients with atherosclerosis. EDV and endothelium-independent vasodilatation were determined by brachial artery infusion of acetylcholine and sodium nitroprusside respectively during measurement of forearm blood flow (FBF) with venous occlusion plethysmography. A 60 min intra-arterial infusion of ET-1 (n l 10) significantly blunted EDV in young healthy males (33p13 % compared with 271p74 % increase in FBF induced by 10 µg/min acetylcholine ; P 0.01). Noradrenaline, which evoked a similar degree of vasoconstriction, did not attenuate EDV. In a separate set of experiments, a 60 min intra-arterial infusion of the selective ET A receptor antagonist BQ123 evoked a significant increase in EDV in patients with atherosclerosis (n l 10 ; 109p45 % compared with 255p101 % increase in FBF induced by 10 µg/min acetylcholine ; P 0.01), whereas no significant change was observed in healthy age-matched controls (n l 9). Endothelium-independent vasodilatation was not affected by ET-1 or BQ123. These observations demonstrate that elevated levels of ET-1 impair EDV in healthy control subjects. Furthermore, ET A receptor blockade improves EDV in patients with atherosclerosis, indicating that ET-1 attenuates EDV via an ET A -receptor-mediated mechanism.
INTRODUCTION
Vascular endothelial cells are known to produce a number of vasoactive mediators, including nitric oxide (NO) [1] and endothelin-1 (ET-1) [2] . These mediators contribute to the maintenance of basal vascular tone and blood pressure in humans [3, 4] . Besides being a vasodilator, NO exerts anti-atherogenic effects through its antiinflammatory properties and by inhibiting vascular Key words: atherosclerosis, endothelins, nitric oxide, regional blood flow, vasodilatation.
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smooth muscle cell proliferation [5] . Previous studies have demonstrated impaired endothelium-dependent vasodilatation (EDV) in both large conduit arteries and small resistance arteries in patients with atherosclerosis [5] . This impaired response is the result of reduced bioavailability of NO, which may be due to reduced production or increased degradation of NO [6] . Moreover, in patients with atherosclerosis, circulating levels of the potent vasoconstrictor peptide ET-1 are elevated [7] and immunoreactive staining for ET-1 is increased in the vasculature [8] . ET-1 mediates vasoconstriction via activation of the two receptor subtypes, ET A and ET B [9, 10] . ET-1 has been demonstrated to be of importance for the progression of atherosclerotic plaques in experimental animals, via an effect mediated by the ET A receptor [11] .
Close interactions appear to exist between NO and ET-1 in the vascular wall. Thus NO inhibits the production of ET-1 in endothelial cells [12] , and ET-1 is known to stimulate the release of NO from healthy arteries via activation of the ET B receptor located on endothelial cells [13] . However, little is known about the consequences of elevated ET-1 levels in atherosclerosis for NO bioavailability and endothelial function. ET receptor antagonism has been reported to improve endothelial function in isolated arteries from apolipoprotein E-deficient mice [11] and in isolated internal mammary arteries from patients with coronary artery desease [14] . The only study performed so far on humans in vivo demonstrated that a low dose, but not a high dose, of an ET A receptor antagonist improved endothelial function in patients with chronic heart failure [15] . Thus it still remains unclear how stimulation and blockade of ET receptors affects endothelial function in humans, and in particular in patients with atherosclerosis. The purpose of the present study was therefore (1) to investigate the effect of elevated levels of ET-1 on EDV in resistance vessels of the human forearm, and (2) to test the hypothesis that ET A receptor antagonism improves EDV in patients with atherosclerosis.
MATERIALS AND METHODS

Subjects
The study included two different experimental protocols. Protocol 1 was performed with young, healthy, nonsmoking, male subjects who received infusions of either ET-1 (protocol 1A ; n l 10) or noradrenaline (protocol 1B ; n l 6). Some basal characteristics of the study population in protocol 1 are presented in Table 1 . Values are given as meanspS.E.M. There were no significant differences between the groups for the characteristics listed.
Parameter ET-1 (n l 10) Noradrenaline (n l 6) Age (years) 29p2 2 6 p1 Mean arterial blood pressure (mmHg) 90p2 9 2 p1 Body mass index (kg/m 2 ) 2 4 p1 2 2 p1 Forearm circumference (cm) 27.5p0.5 27.2p0.7 Protocol 2, in which the subjects received the selective ET A receptor antagonist BQ123, was performed on 10 male patients with atherosclerosis and on nine male healthy age-matched controls. Some basal characteristics of the study population in protocol 2 are presented in Table 2 . The patients had symptoms of intermittent claudication with significant atherosclerotic lesions and flow obstructions in the large arteries of the legs, as determined by ultrasound scanning and\or angiography. All patients also had coronary artery disease (previous myocardial infarction or angina pectoris that had required coronary revascularization). None of the patients had any history of congestive heart failure or diabetes mellitus. Two of the patients were treated hypertensives. The age-matched control subjects were normotensive, without a history of cardiovascular disease and with normal ankle\brachial pressure index and pulse curves in the dorsalis pedis artery. None of the subjects had any evidence of significant stenotic lesions or flow obstructions in the brachial artery, as determined by ultrasound scanning. The patients were on regular medication with β-blockers (n l 6), long-acting nitrates (n l 3), calcium channel blockers (n l 3), statins (n l 2), angiotensin II receptor antagonists (n l 2) or acetylsalicylic acid (n l 8). All medication with vasodilator properties (i.e. nitrates, calcium channel blockers and angiotensin II receptor antagonists) was withheld for at least four halflives prior to the investigation. On the morning of the investigation, the patients did not take any of their regular medication. None of the control subjects was on any medication. Both patients and control subjects were given 320 mg of acetylsalicylic acid the day before and on the day of the examination to block a possible ETinduced release of cyclo-oxygenase products.
Informed consent was obtained from all subjects. The investigation was carried out in accordance with the Declaration of Helsinki (1989) of the World Medical Endothelin-1 and endothelial dysfunction Values are given as meanspS.E.M. Significance of differences : *P 0.05 compared with saline infusion alone.
Association, and was approved by the human ethics committee of the Karolinska Hospital.
Experimental protocols
The investigations were performed with the subjects in the supine position in a quiet laboratory with controlled temperature. The subjects were allowed a light breakfast without caffeine-containing drinks or alcohol, and were instructed not to smoke on the day of the study. A percutaneous catheter was inserted under local anaesthesia in the proximal direction into the brachial artery of the non-dominant arm for infusions. Forearm blood flow (FBF) was measured simultaneously in both arms by venous-occlusion plethysmography using a mercury-insilastic strain gauge (protocol 1) or an air-filled cuff (protocol 2) applied around the widest part of the forearm [16] . A cuff placed around the upper arm was inflated to 50 mmHg for 10 s in order to obstruct the venous outflow during the recording of FBF. The circulation in the hands was occluded by inflating a wrist cuff to 30 mmHg above systolic blood pressure. An infusion of 0.9 % NaCl (0.5 ml\min) was given continuously into the brachial artery during baseline recordings. At 30 min after arterial cannulation, basal FBF was determined during an additional infusion of saline for 2 min at a rate of 2.5 ml\min.
Characterization of EDV
The degree of NO-dependent vasodilatation evoked by acetylcholine and substance P was evaluated before carrying out the two study protocols, in seven healthy, non-smoking control subjects (age 24p1 years) as follows. Acetylcholine (10 and 30 µg\min) or substance P (2 and 6 pmol\min) were infused into the brachial artery at a rate of 2.5 ml\min (2 min per dose), together with a continuous infusion of saline (0.5 ml\ min). The NO synthase inhibitor N G -monomethyl-Larginine (L-NMMA ; 1 mg\min) was then infused for 45 min. L-NMMA decreased FBF by 19p5% (P 0.01). After a 15 min infusion of L-NMMA, basal FBF was restored by co-infusion of sodium nitroprusside (SNP ; 0.1-0.3 µg\min) for 5 min before the infusions of acetylcholine and substance P were repeated. The vasodilator response to both doses of acetylcholine was significantly blunted during co-infusion of L-NMMA and SNP (Figure 1) . However, the vasodilator response to substance P was not altered significantly, although there was a trend towards impaired vasodilatation during coinfusion with L-NMMA. Therefore in the subsequent two study protocols only acetylcholine was used to evaluate changes in endothelial function.
Protocol 1
In this protocol (Figure 2 ), EDV was determined by infusion of acetylcholine (10 and 30 µg\min) at a rate of 2.5 ml\min together with saline (0.5 ml\min) into the brachial artery. Each dose was given over 2 min. ET-1 (10 pmol\min ; protocol 1A) or noradrenaline (80 ng\ min ; protocol 1B) was then infused for 80 min at a rate of 0.5 ml\min ; after 60 min, the infusions of acetylcholine were repeated. In the subjects receiving ET-1, the NO donor SNP (10 µg\min) was also infused before and during infusion of ET-1 for the determination of endothelium-independent vasodilatation. Blood pressure was measured before and after the infusions.
Protocol 2
In this protocol (Figure 2 ), acetylcholine (10 and 30 µg\min) and SNP (10 µg\min) were infused as described above, before and after a 60 min infusion of the selective ET A receptor antagonist BQ123 (10 nmol\min) into the brachial artery at a rate of 0.5 ml\min. Blood pressure was recorded before and after the infusions.
Drugs
BQ123 (Clinalfa AG, La$ ufelfingen, Switzerland) was dissolved in sterile 0.9 % NaCl and stored frozen at k80 mC. L-NMMA (Alexis Corp., La$ ufelfingen, Switzerland), ET-1 and substance P (Peninsula Laboratories, Warrington, Merseyside, U.K.) were dissolved in 0.9 % NaCl, sterile-filtered through a Millipore filter and thereafter stored frozen at k80 mC. On the day of the experiments, all substances were diluted to the correct concentrations in sterile 0.9 % NaCl.
Calculations
FBF was calculated as the mean of eight inflow recordings during 2 min. The ratio of flows in the infused and the non-infused arm at each time point is expressed as Protocol 1 : two doses of acetylcholine (10 and 30 µg/min) and one dose of SNP (10 µg/min) were given during saline infusion and again following a 60 min infusion of ET-1 to 10 healthy subjects (protocol 1A). In another six individuals (protocol 1B), acetylcholine was given during saline infusion and following a 60 min infusion of noradrenaline (NA). Protocol 2 : acetylcholine and SNP were given during saline infusion and again following a 60 min infusion of the ET A receptor antagonist BQ123 in patients with atherosclerosis (n l 10) and in age-matched controls (n l 9).
percentage change from baseline. All data are given as mean valuespS.E.M. Statistical differences were calculated using the non-parametric paired sign test for between-group comparisons, or the Kruskal-Wallis test for repeated measures. P 0.05 was regarded as significant.
RESULTS
Protocol 1 : infusions of ET-1 and noradrenaline
None of the infusions evoked any changes in heart rate, blood pressure or FBF in the non-infused arm. Mean absolute FBF in the infused arm is shown in Table 3 .
Both doses of acetylcholine caused marked increases in FBF during saline infusion (P 0.001 ; Figure 3A ). ET-1 decreased FBF by 53p7 % (Table 3 ; P 0.001). The vasodilator effect of both doses of acetylcholine was significantly blunted after a 60 min infusion of ET-1 (Table 3 ; Figure 3A ). The percentage increase in FBF evoked by SNP was enhanced during infusion of ET-1 (P 0.05 ; Figure 3B ).
Noradrenaline decreased FBF by a magnitude similar to that induced by ET-1 (45p9 %). The absolute increase in FBF evoked by acetylcholine was not affected by noradrenaline (Table 3) , but, because of the decrease in baseline FBF, the percentage increase in FBF evoked by Values are given as meanspS.E.M. Significant differences in flow during infusion of acetylcholine (ACh) and SNP in the presence or absence of ET-1 (protocol 1A) or noradrenaline (NA ; protocol 1B) are shown : **P 0.01. acetylcholine was significantly greater during infusion of noradrenaline than during saline infusion ( Figure 3C ).
Protocol 2 : infusion of BQ123
There were no significant changes in heart rate, blood pressure or FBF in the non-infused arm in either the Endothelin-1 and endothelial dysfunction patients or the controls. Both doses of acetylcholine increased FBF in both patients and controls ( Figure 4) . The vasodilator response to acetylcholine during saline infusion in the age-matched control subjects was slightly but non-significantly greater than that in the patients, but significantly smaller than that obtained in the younger controls included in protocol 1 (P 0.01). Infusion of the selective ET A receptor antagonist BQ123 increased FBF to a similar extent in both patients and controls (39p11 % and 41p11 % respectively ; P 0.05 for both). In the patients, the vasodilator responses to the Values are given as meanspS.E.M. Significance of differences : *P 0.05, **P 0.01 compared with saline infusion.
two doses of acetylcholine were significantly enhanced during infusion of BQ123 ( Figure 4A ). In the controls, on the other hand, there were no significant differences in the vasodilatation induced by acetylcholine before and during infusion of BQ123. The percentage increase in FBF induced by acetylcholine (10 µg\min) following BQ123 as compared with during saline was significantly greater in the patients than in the controls (75p13 % and 41p30 % respectively ; P 0.05). The vasodilator response to SNP was not affected by administration of BQ123 in the patients or controls ( Figure 4B ).
DISCUSSION
The main findings of the present study are that ET-1 significantly decreases EDV induced by acetylcholine in the forearm of healthy humans, and that selective ET A receptor blockade significantly improves EDV in patients with atherosclerosis. These findings suggest that elevated levels of ET-1 impair endothelial function in the human forearm, and that impaired EDV in patients with atherosclerosis can be improved by ET A receptor blockade. The vasodilator response to acetylcholine was markedly attenuated during administration of ET-1. The finding that L-NMMA significantly decreased the vasodilator response to acetylcholine indicates that its effect is mediated in large part by NO, as described in previous studies [17] [18] [19] . During the infusion of ET-1, FBF was reduced by approx. 50 % ; this may have affected the concentration of acetylcholine in the forearm, since acetylcholine is known to be inactivated rapidly and its biological activity altered by changes in blood flow [20, 21] . For control purposes, noradrenaline was infused at a dose that lowered FBF to a similar extent. The vasodilator response to acetylcholine was not reduced during noradrenaline infusion. This finding clearly demonstrates that the decreased vasodilator response to acetylcholine during ET-1 infusion is not due to reduced FBF per se and thereby an increase in acetylcholine degradation. The percentage increase in FBF induced by the endothelium-independent vasodilator SNP was not attenuated during infusion of ET-1. Therefore a likely mechanism behind the decreased vasodilator response to acetylcholine during ET-1 infusion is reduced bioavailability of endogenous NO.
The second part of the study (protocol 2) was aimed at investigating the involvement of endogenous ET-1 in the impaired EDV in patients with atherosclerosis. Selective ET A receptor blockade increased FBF to a similar extent in both patients with atherosclerosis and healthy agematched controls. Acetylcholine evoked similar degrees of vasodilatation before ET A receptor blockade in both patients and controls, although there was a marginally larger mean response in the controls. Following 60 min of administration of the ET A receptor antagonist, EDV was significantly enhanced in the patients. The finding that the vasodilator response to acetylcholine during ET A receptor blockade was enhanced in the patients, but not in the controls, suggests that there is a greater inhibitory effect of endogenous ET-1 on NO bioavailability acting through the ET A receptor in the patients. This may be in accordance with previous findings of enhanced expression of ET-1 in atherosclerotic arteries [7] . The general capacity of the forearm resistance vessels to dilate was not changed by ET A receptor blockade, since the vasodilator response to SNP was similar in both patients and controls before and during infusion of BQ123. Accordingly, the enhanced vasodilator response to acetylcholine during ET A receptor blockade in the patients appears to have been due to increased bioavailability of endogenous NO.
Endothelial dysfunction is an early sign of atherosclerosis [22, 23] . Several traditional risk factors for atherosclerosis have been implicated in the observed abnormal endothelial function. The present study suggests that ET-1 contributes to this impaired EDV. The expression of ET-1 is up-regulated and plasma levels of ET-1 are increased in patients with atherosclerosis [7, 8] . ET A receptor blockade has been demonstrated previously to improve EDV in isolated arterial preparations from atherosclerotic mice [11] and in isolated internal mammary arteries from patients undergoing coronary artery bypass surgery [14] . However, little is known about the effect of ET receptor blockade on EDV in patients in vivo. In a recent study it was demonstrated that a low dose of the ET A receptor antagonist LU 135252 improved brachial artery EDV in patients with chronic heart failure [15] . However, the effect was not reproduced with a higher dose, which complicates the interpretation. The findings of the present study demonstrate both that EDV is impaired by elevated circulating levels of ET-1 in healthy individuals and that impairment of EDV is improved by ET A receptor blockade in patients with atherosclerosis. The mechanism by which ET-1 reduces the bioavailability of NO remains to be clarified. One interesting possibility is that ET-1 increases superoxide production in the vascular wall [24, 25] via an effect that seems to be coupled to the ET A receptor [26] . Superoxide will react with NO released from the endothelium and thereby reduce its bioavailability. Other mechanisms, such as decreased availability of L-arginine or reduced NO synthase activity, may also be involved.
EDV was determined by infusion of acetylcholine, which was characterized to be NO-dependent to a large extent, in agreement with previous findings [17, 18] . EDV was greater in the young healthy controls of protocol 1 than in the older controls included in protocol 2, although blood pressure and smoking habits were similar in the two groups. These findings are in agreement with previous observations suggesting that endothelial function is reduced at an older age [27] , although other uncontrolled factors, such as cholesterol levels, may have contributed to this difference. It was also noted that there was a trend towards an inverse dose-response relationship for acetylcholine in the patients with atherosclerosis. This may be related to the fact that acetylcholine causes constriction via activation of muscarinic receptors on vascular smooth muscle cells. In patients with severe endothelial dysfunction, acetylcholine may therefore evoke vasoconstriction at high doses [28] .
There were no differences between patients and control subjects in basal FBF, and there were no changes in blood flow in the control arm or in systemic blood pressure in either protocol. Therefore it seems unlikely that differences in autonomic vasomotor tone interfered with the observed changes in blood flow. A limitation of the present study is that the vascular effects were investigated in the forearm. It may be argued that the forearm circulation does not properly reflect changes in other vascular beds. However, atheromatous lesions in arteries of the forearm correlate with atherosclerotic lesions in arteries of other vascular beds, such as coronary arteries and carotid arteries [29] .
In conclusion, the present study demonstrates that elevated levels of ET-1 impair EDV in the human forearm in vivo. Furthermore, ET A receptor blockade improves EDV in patients with atherosclerosis, indicating an enhanced ET A -receptor-mediated inhibitory effect of ET-1 on NO bioavailability in vivo in these patients. These findings may have important therapeutic implications, since impaired EDV is an early marker of endothelial dysfunction [22, 23] and a prognostic factor in the progression of atherosclerotic disease [30] . ET A receptor blockade may represent one way of improving impaired endothelial function in patients with atherosclerosis.
